Table 1. Clinical and functional characteristics of the patients.
IPFN = 26 | SSc-ILDN = 9 | ControlsN = 11 | |
Age (years) | 74 [56–84] | 62 [46–72]* | 68 [34–79]* |
Gender (Male) | 19 (73%) | 4 (44%) | 9 (81%) |
Smoker (ever) | 16 (61%) | 2 (22%) | 9 (81%) |
Delay since diagnosis(days) | 17.5 [0–655] | 146 [5–525] | na |
Oral Steroids | 6 (23%) | 1 (11%) | 0 |
Dose (mg) | 8.7 [5–40] | 10 | na |
Exacerbation | 3 (11%) | 0 | na |
Progression | 13 (48%) | 0 | na |
Lung Function Tests | |||
TLC (% pred) | 68 [28–105] | 56 [35–94] | 88 [50–118]* |
VC (% pred) | 75 [34–108] | 57 [29–134] | 102 [52–109] |
DLCO (% pred) | 35 [15–91] | 33 [16–85] | Not available |
PaO2 (mmHg) | 76 [45–101] | 90 [39–99] | Not available |
Pulmonaryhypertension (N) | 3 (11%) | 3 (33%) | 0 |
Data are expressed as median [range] or N (%); na: not applicable. *p<0.05.